Steven Weinstein

Managing Director

Steve is a Managing Director in Novartis Venture Fund’s Cambridge, MA office. Steve focuses on both medical device and bio/pharma investments for the fund. He brings significant operating and venture capital experience to Novartis’ investing efforts. Steve joined the Fund in 2006 as a Managing Director. He has led the investments and serves/d on the board of the following companies: Ablation Frontiers (acquired by Medtronic), Autonomic Technologies Inc.,Intersection Medical, Portaero, Sonitus Medical, and Visiogen (acquired by Abbott) Prior to Novartis, Steve was at Prism Venture Partners, where he focused on medical devices and served on the boards of iScience Interventional, and Sensitech (acquired by Carrier/UTX). Prior to Prism, Steve was a Kauffman Fellow with Mid-Atlantic Venture Funds. He started his career as an entrepreneur and CEO, raising angel funds to buy the assets of a defunct distribution business out of bankruptcy, and then rebuilt the business over the next five years. Steve holds an MBA with distinction from the University of Michigan Business School and a BS in mechanical engineering from Columbia University’s School of Engineering and Applied Science. He serves on the Innovation Advisory Board of the Cleveland Clinic, the Innovation Advisory Board of Partners Healthcare, and is a member of the Virginia GAP BioLife Fund Investment Committee.